Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Methylmalonic Acidemia (MMA) Market In 2029?

The market size for methylmalonic acidemia (MMA) has witnessed robust growth in the past few years. The industry is projected to expand from $9.39 billion in 2024 to $9.94 billion in 2025, resulting in a compound annual growth rate (CAGR) of 5.9%. The historical growth of this market can be linked to the uptick in occurrences of metabolic disorders and vitamin deficiencies, heightened healthcare spending, an increase in health awareness, a rise in genetic disorders prevalence, along with a surge in demand from diverse end-user industries.

In the coming years, the methylmalonic acidemia (mma) market is anticipated to experience robust growth, reaching a value of $12.4 billion in 2029, representing a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth include the expansion of newborn screening programs, an increase in awareness among medical practitioners, advancements in gene therapy, increased funding for research on rare diseases and the growing availability of specialized treatments. Key trends that will shape the market during the forecast period are developments in gene editing technologies, improved diagnostic methods for early detection, advancements in enzyme therapy, the application of precision medicine strategies and the implementation of newborn genetic screening programs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Methylmalonic Acidemia (MMA) Market?

The growth of the methylmalonic acidemia (MMA) market is likely to be fueled by the rising occurrence of metabolic disorders and vitamin deficiencies. Metabolic disorders, a series of conditions where the body encounters difficulty in energy production, nutrient processing, or chemical reaction regulation, along with vitamin deficiencies, where the body does not acquire enough specific vitamins for normal functions, are on the rise. This surge can be attributed to unhealthy diets, sedentary lifestyles, and elevated stress levels. Contemporary diets, packed with processed foods, sugars, and unhealthy fats but lacking essential nutrients, contribute to vitamin and mineral deficiencies. Especially when it comes to vitamin B12 deficiency, these conditions impair methylmalonyl-CoA metabolism, resulting in accumulation of methylmalonic acid and worsening methylmalonic acidemia (MMA). To illustrate, the National Institutes of Health, a US-based government agency, reported in November 2024 that prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, indicating an added 507 cases between the third and fourth quarters of 2023. It is thus evident that the escalating incidence of metabolic disorders and vitamin deficiencies propels the expansion of the methylmalonic acidemia (MMA) market.

Which Key Market Segments Comprise the Methylmalonic Acidemia (MMA) Market and Drive Its Revenue Growth?

The methylmalonic acidemia (mma)market covered in this report is segmented –

1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications

2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria

3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels

Subsegments:

1) By Acidosis: Metabolic Acidosis; Lactic Acidosis

2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis

3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia

4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi

5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia

6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia

7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Which Areas Are Leading Regions in the Methylmalonic Acidemia (MMA) Market Expansion Across the Globe?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theMethylmalonic Acidemia (MMA) Market Direction?

Key businesses in the methylmalonic acidemia (MMA) market are excitedly concentrating on innovative solutions like mRNA-based therapies. The goal is to enhance treatment results by specifically addressing the fundamental genetic sources of MMA and intensifying the enzyme function to minimize the buildup of harmful metabolites in suffering individuals. mRNA-based therapies, which deploy messenger RNA to guide cells in creating particular proteins, can be pivotal in countering ailments like genetic health issues or infections. For example, in June 2024, Moderna, Inc., an American pharmaceutical and biotech firm, earned approval from the U.S. Food and Drug Administration (FDA) for the inclusion of mRNA-3705 in the START pilot scheme, thus marking a vital leap forward in creating remedies for rare diseases. mRNA-3705 is an experimental treatment for methylmalonic acidemia (MMA) brought about by MUT shortcomings, and aims to replace the absent enzyme through mRNA technology. Moderna’s proprietary lipid nanoparticle (LNP) system, which is also leveraged in the mRNA-3927 program for propionic acidemia, is applied in the therapy. The FDA has bestowed mRNA-3705 with orphan drugs, fast track, and rare pediatric disease statuses, which will considerably hasten its development and clinical advancement.

View the full report here:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

How Is the Methylmalonic Acidemia (MMA) Market Conceptually Defined?

Methylmalonic acidemia (MMA) is a rare, inherited metabolic disorder in which the body is unable to properly break down specific proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The symptoms of MMA can vary in severity but often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model